In the present study, we analyzed the effect of DLL3 expression on overall survival (OS) and recurrence free survival (RFS) in LCNEC and further analyzed the predictability of this expression for the efficacy of adjuvant chemotherapy. This evidence concerns the gene DLL3 and large cell neuroendocrine carcinoma.